Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Cormedix Inc
CRMD
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$7.57
0.19
2.57%
Dern. MÀJ: Oct 20, 6:30 PM
$7.60
0.22
2.98%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Cormedix Financials
Cormedix (CRMD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
CorMedix Stock Jumps on Strong DefenCath Sales
CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.
Vandana Singh
PRO
Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate
Benzinga Newsdesk
PRO
Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $334.089M Est
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $334.089 million estimate.
Benzinga Newsdesk
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
CorMedix raises 2026 guidance after Q1 revenue surges on strong DefenCath demand and higher profitability.
Vandana Singh
PRO
Cormedix Raises FY2026 Sales Guidance from $300.000M-$320.000M to $325.000M-$345.000M vs $308.224M Est
Cormedix (NASDAQ:CRMD) raises FY2026 sales outlook from $300.000 million-$320.000 million to $325.000 million-$345.000 million vs $308.224 million estimate.
Benzinga Newsdesk
PRO
Cormedix Q1 Adj. EPS $0.43 Beats $0.36 Estimate, Sales $127.427M Beat $105.017M Estimate
Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.36 by 16.22 percent. This is a 43.33 percent increase over earnings of $0.30 per share from the same
Benzinga Newsdesk
